Prostate Cancer (PCa) is a leading cause of cancer-related death in American men. Like other cancers, PCa develops in the background of intrinsic cues and extrinsic factors. Distinct sets of genes and proteins dictate progression from precursor lesion of the prostate, to localized PCa, and finally to metastatic disease. Clinically localized PCa can be effectively ablated using surgical or radiation treatments. Hormone-refractory metastatic disease, however, is invariably incurable and leads to death. Therefore, characterizing the genes that regulate the growth of metastatic PCa are of particular relevance to prostate cancer research and may offer novel targets for therapeutic intervention. One of these genes we identified was EZH2, a Polycomb group protein that is up-regulated in aggressive cancers. Dysregulation of EZH2 promotes tumor progression through the repression of a key set of tumor suppressor genes, including ADRB2, a critical regulator of the beta-adrenergic signaling pathway. ADRB2 is a direct target of EZH2-mediated transcriptional repression and may serve as a prognostic biomarker in PCa. However, ADRB2 function and its downstream cellular signaling cascade in PCa remain unclear. My long-term goal is to understand the molecular machineries regulating cancer progression. The objective of this application is to characterize the role of ADRB2 in PCa. Our central hypothesis is that dysregulated expression of ADRB2 promotes prostate cancer progression through disrupted cellular signaling pathways, The specific aims of this proposal will be as follows:
Specific Aim 1 : Determine expression pattern and clinical correlation of ADRB2 in prostate cancer.
Specific Aim 2 : Characterize the role of ADRB2 in regulating prostate cancer growth and development.
Specific Aim 3 : Understand the mechanism of ADRB2 as a tumor suppressor in prostate cancer. In summary, this proposal addresses the expression, functional roles, and underlying mechanisms of ADRB2 in the growth and development of prostate cancer. Our ultimate hope is that the functional characterization of ADRB2 in metastatic prostate cancer will one day lead to an effective therapy for this invariably lethal disease.
| Wu, L; Runkle, C; Jin, H-J et al. (2014) CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene 33:504-13 |
| Kim, J; Wu, L; Zhao, J C et al. (2014) TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene 33:5183-92 |
| Wu, Longtao; Zhao, Jonathan C; Kim, Jung et al. (2013) ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Res 73:6068-79 |
| Jin, Hong-Jian; Zhao, Jonathan C; Ogden, Irene et al. (2013) Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res 73:3725-36 |
| Yang, Yeqing Angela; Yu, Jindan (2013) EZH2, an epigenetic driver of prostate cancer. Protein Cell 4:331-41 |
| Jin, Hong-Jian; Kim, Jung; Yu, Jindan (2013) Androgen receptor genomic regulation. Transl Androl Urol 2:157-177 |
| Wang, Lan; Zeng, Xianzhuo; Chen, Shuai et al. (2013) BRCA1 is a negative modulator of the PRC2 complex. EMBO J 32:1584-97 |
| Kim, Jung; Yu, Jindan (2012) Interrogating genomic and epigenomic data to understand prostate cancer. Biochim Biophys Acta 1825:186-96 |
| Zhao, Jonathan C; Yu, Jianjun; Runkle, Christine et al. (2012) Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res 22:322-31 |
| Kappes, Ferdinand; Waldmann, Tanja; Mathew, Veena et al. (2011) The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes Dev 25:673-8 |
Showing the most recent 10 out of 17 publications
